logoslogan
home3.jpg

We are a venture capital firm investing in life science companies covering start-ups to later stage companies. Based in Heidelberg, we invest throughout Europe with the aim to build companies that create significant commercial opportunities based on new therapeutic treatment modalities and pharmaceuticals, next generation enabling technology platforms or innovations in the diagnostics and medical device area. As an independent and focused team we move quickly with short decision timelines. However, once engaged, we offer our portfolio companies the time and the attention they deserve to make them sucessful.

EMBL Ventures manages two Funds with a total of € 68m capital on behalf of major European private and institutional investors. We prefere a role as lead or co-lead investor in  financing rounds which typically range from € 5m to € 30m. Our total commitment in a single portfolio company can go as high as € 8m.

As with our portfolio companies each Partner at EMBL Ventures strives to build long-lasting personal relationships with Investors in our Funds, such as institutionals, high net-worth individuals and familiy offices. These relationships are based on EMBL Ventures' core values of open and prompt communication coupled with the ambition to generate maximum return.

Crescendo Biologics' Receives Further Investment from Astellas Venture Management to Develop Novel Humabody™ Therapeutics Targeting Immune Checkpoint Inhibitors

Crescendo Biologics Limited (Crescendo) today announces a further equity investment from Astellas Venture Management (AVM) to support the discovery and development of new Humabody™ antibody fragment therapeutics in oncology. Financial details were not disclosed.

Continue Reading

ImevaX secures €7.5 million in Series A Financing to develop highly specific vaccine against Helicobacter pylori infections

ImevaX GmbH, a specialist in vaccines against pathogens of chronic infectious diseases, announces today the completion of a €7.5 million Series A financing round.

Continue Reading

Lipid Therapeutics' European partner Dr. Falk Pharma GmbH enrolls first patients into pivotal Phase III trial with LT-02, a novel therapy for ulcerative colitis (UC)

Positive FDA feedback on the protocol for the US Phase III trial with LT-02, a key element of the product's global development program

Continue Reading